The server is under maintenance between 08:00 to 12:00 (GMT+08:00), and please visit later.
We apologize for any inconvenience caused
Login  | Sign Up  |  Oriprobe Inc. Feed
China/Asia On Demand
Journal Articles
Laws/Policies/Regulations
Companies/Products
Bookmark and Share
Research progress on non-small-cell lung cancer drugs targeting Met
Author(s): 
Pages: 562-566
Year: Issue:  4
Journal: World Phytomedicines

Keyword:  targeted therapy drugsnon-small-cell lung cancerdriver gene;
Abstract: Following the gene mutation of epidermal growth factor receptor(EGFR) and gene fusion of anaplastic lymphoma kinase(ALK), Met activating mutations and gene amplification are considered to be the next important driver gene of non-small-cell lung cancer(NSCLC), which is associated with tumor proliferation, invasion, metastasis, and angiogenesis. And this has become a major aspect of tumor targeted therapy research. The main targeted therapy drugs can be divided into anti-HGF monoclonal antibody, anti-c-Met monoclonal antibodies and small molecule inhibitors, and more of them have entered clinical trials. This review focuses on the latest research on c-Met and its targeted therapy drugs.
Related Articles
No related articles found